Next Article in Journal
Impact of Cooking Techniques on the Dietary Fiber Profile in Selected Cruciferous Vegetables
Previous Article in Journal
Molecular Dynamics-Assisted Discovery of Novel Phosphodiesterase-5 Inhibitors Targeting a Unique Allosteric Pocket
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 30
Issue 3
10.3390/molecules30030589
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Studies of the Synthesis of Fused Isoxazoline/Isoquinolinones and Evaluation of the Antifungal Activity of Isoxazole-like Benzamide and Isoquinolinone Hybrids

by
Konstantinos A. Ouzounthanasis
1,
Jasmina Glamočlija
2,
Ana Ćirić
2 and
Alexandros E. Koumbis
1,*
1
Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2
Department of Plant Physiology, Institute for Biological Research “Siniša Stanković”—National Institute of Republic of Serbia, University of Belgrade, 11060 Belgrade, Serbia
*
Author to whom correspondence should be addressed.
Molecules 2025, 30(3), 589; https://doi.org/10.3390/molecules30030589
Submission received: 28 December 2024 / Revised: 26 January 2025 / Accepted: 26 January 2025 / Published: 27 January 2025
(This article belongs to the Section Organic Chemistry)
Browse Figures
Versions Notes

Abstract

:
Isoxazole derivatives (isoxazoles, isoxazolines, and isoxazolidines) are present in the structure of several natural products and/or pharmaceutically interesting compounds. In this work, a synthetic study for the preparation of fused isoxazoline/isoquinolinone hybrids is presented. The initial approach involving the sequential 1,3-dipolar cycloaddition of nitrile oxides to indenone (to obtain the isoxazoline ring) and a Beckmann rearrangement (to construct the isoquinolinone lactam system) was complicated by the formation of fragmentation products during the latter. Therefore, the desired hybrids were successfully reached by applying DDQ-mediated oxidation of the respective isoxazolidines. Based on the results, key observations were made regarding the mechanism of the Beckmann reaction. Moreover, selected isoxazole benzamides and fused isoxazoline/isoxazolidine isoquinolinones were in vitro evaluated against a series of fungi strains (including a 2D checkerboard assay with ketoconazole), revealing that some of these compounds exhibit promising antifungal activity.

Graphical Abstract

1. Introduction

Isoxazoles, isoxazolines, and isoxazolidines constitute families of five-membered heterocycles with diverse applications [1,2,3]. In synthetic organic chemistry, those heterocycles may serve as valuable building blocks for constructing more complex compounds upon further functionalization (e.g., Scheme 1, [4]). Additionally, numerous biologically active molecules and pharmaceutical compounds incorporate these moieties as integral structural features [5,6,7]. It is worth noting that even though the isoxazolidine ring scaffold has been found in natural products [8,9,10] (Scheme 2A), isoxazoles and isoxazolines have been widely employed in medicinal chemistry as tools of synthetic modifications of natural products to enhance various properties (pharmacokinetics, activity, selectivity, etc.), thereby optimizing drug candidates [11,12] (e.g., Scheme 2B). In particular, a significant number of isoxazole-like compounds have been found to exhibit antifungal activity [7,13,14,15,16].
In our previous work [17], we reported a couple of concise synthetic strategies for accessing novel isoxazole (7) and isoxazolidine (10a,b) hybrid compounds (Scheme 3A,B) as the result of merging these five-membered heterocycles with the privileged scaffold of isoquinolinone [18] and several new isoxazole benzamide precursors. Those hybrids represent the first reported derivatives of isoquinolinone with the isoxazole and isoxazolidine ring fused at C3 and C4 of the isoquinolinone template. To our knowledge, references regarding fused isoquinolinones with five-membered heterocycles at the aforementioned positions are exceptionally rare, despite the potential of such compounds to show alluring activity against a wide range of biological targets [19]. However, establishing a dependable methodology for the facile preparation of the corresponding isoxazoline/isoquinolinone fused hybrids (11) proved to be a rather challenging task (Scheme 3C).
Fungal infections trigger about 1.7 million deaths per year worldwide, mostly in immunocompromised individuals with two or more pathological conditions [20]. With the widespread use of antifungal drugs, the prevalence of resistance to each drug has also increased. Therefore, new drugs need to be developed that are more effective and have fewer side effects, as both fungi and mammals are eukaryotes and, therefore, have many common drug targets. Thanks to advances in medical technology and research, new drugs can now be developed that are more effective against fungal infections. In addition, new antifungal strategies, innovative delivery methods, and synergistic approaches are needed.
Most fungal infections are caused by Candida, Cryptococcus, and Aspergillus species, which kill more than one million people every year [21]. The species responsible for Aspergillus infections mainly include Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Aspergillus niger [22]. Although Candida albicans is often found as part of the healthy human microbiome, it is one of the most common fungal pathogens in humans. Recurrent infections, antimicotic resistance, and a mortality rate of up to 54% for candidiasis indicate that this species poses a serious risk to human health and a significant economic burden to our society [23]. Several Penicillium species, such as P. chrysogenum, are known to be both allergens and pathogens. Penicillium spores can be detected in the air throughout the year, but they can also show seasonal fluctuations. They can cause a variety of infections, especially in people with a weakened immune system due to an existing disease [24]. The treatment of choice for invasive diseases recently expanded to first-line treatments, and azole resistance represents an emerging problem, with primary resistance observed in several fungal species.
Herein, we report our efforts to develop a new synthetic strategy for accessing hybrid compounds 11 (Scheme 3C), ultimately leading to a complete collection of isoquinolinone fused hybrids with the isoxazole family of five-membered heterocycles, making these compounds readily available for extensive biological screening. Additionally, we present the in vitro antifungal activity evaluation of selected compounds of isoxazoline and isoxazolidine isoquinolinone and isoxazole benzamide libraries (prepared in this work or as previously described by us [17]) against Aspergillus, Penicillium, and Candida species, as well as the evaluation of the vitro combination of ketoconazole with the compounds that showed the best antifungal activity.

2. Results and Discussion

2.1. Retrosynthetic Plans for the Targeted Hybrids

As a more direct approach to obtaining the desired hybrid compounds, we envisioned the 1,3-dipolar cycloaddition of N-substituted isoquinolinone 12 with various nitrile oxides. An alternative route for preparing the target compounds could involve a Beckmann rearrangement of tosyl oxime 13. The latter can be prepared from ketone 14, which are the adducts of an alkene–nitrile oxide 1,3-dipolar cycloaddition reaction to indenone (8) (Scheme 4). In the next section, we thoroughly discuss the challenges encountered during the process, our attempts to overcome them, and the successful synthesis of some isoxazoline/isoquinolinone hybrids.

2.2. Attempted Synthesis Directly from Isoquinolinone

In our initial synthetic approach, isoquinolinone 15 was treated with NaH in DMF and an appropriate electrophile, affording the respective N-substituted isoquinolinones 16a [25] and 16b in excellent yields (Scheme 5). The preparation of 16 was deemed necessary to disrupt the aromaticity of isoquinolinone in an attempt to enable it to participate as the dipolarophile partner in the subsequent 1,3-cycloaddition reaction. Hydroxamoyl chloride precursor 17a [17] was used for the in situ preparation of the model nitrile oxide to investigate the various conditions of the desired cycloaddition reaction. Both 16a and 16b were refluxed in toluene for 24 h without any sign of the desired product forming. Similarly, conducting the reaction under microwave irradiation at 160 °C also failed to afford isoxazoline cycloadducts (Scheme 5). Additionally, Lewis acids were employed as additives to facilitate the reaction. Triflate salts of various metals [M(OTf)x] were used for this purpose; however, none of the catalysts employed yielded the desired product (Scheme 5). In all cases, isoquinolinone 16a was recovered intact, whereas the deprotection of N-Boc starting material 16b was observed with all metal triflates, except Sc(OTf)3. There are several examples of N-vinyl amides in the literature participating in 1,3-dipolar cycloaddition reactions without any difficulties [26,27]; hence, we assume that the nitrogen atom in combination with the bicyclic structure of isoquinolinone is the main issue preventing the substrate from acting as a dipolarophile.
In a final attempt, the reaction of N-benzyl isoquinolinone 16a with benzaldoxime (19) in the presence of tBuOCl in benzene [28] resulted in the degradation of the starting materials (Scheme 6).
Conclusively, despite the fact that isoquinolinone was ‘trapped’ in its non-aromatic tautomeric form, it failed to act as a dipolarophile in a 1,3-dipolar cycloaddition under both conventional heating and microwave irradiation, even under Lewis acid catalysis conditions. At this point, it was clear that this approach for more direct access to isoxazoline/isoquinolinone hybrid compounds was not feasible.

2.3. Exploring the Synthesis of Isoxazoline/Isoquinolinone Hybrids via Beckmann Rearrangement

Based on our assumption that the main issue lies in the presence of the nitrogen atom already existing in the structure of the substrate, the cycloaddition reaction could be conducted on a different bicyclic starting material. Subsequently, the nitrogen atom could be introduced through a rearrangement reaction. This general strategy had been successfully exploited by us [17] for the preparation of isoxazolidine adducts. Thus, indenone (8) could serve as the new dipolarophile, and after proper modifications, a Beckmann rearrangement could introduce the amide functional group. Due to its instability, indenone (8) was synthesized in situ from 3-bromoindan-1-one (20) prior to the cycloaddition reaction [17], ensuring the integrity of the methodology. Moreover, the required hydroxamoyl chlorides were prepared from the corresponding aldehydes using a known general approach [17].
The cycloaddition reaction between 8 and the nitrile oxide derived from benzaldehyde has already been presented in our previous work [17]. Following a similar logic, the previously prepared hydroxamoyl chloride 17 and bromide 20 were treated with Et3N in DCM (Table 1). The reaction proceeded smoothly in all cases, affording regioselectively the major cycloadduct 14 in very good yields. In most instances, the minor cycloadduct 21 was also isolated, albeit in meager yields. The predominance of cycloadduct 14 is not surprising since indenone as an α,β-unsaturated ketone should favor the approach of the negatively charged oxygen atom of the 1,3-dipole to the less electron-rich β-carbon.
To avoid the more conventional methods for the rearrangement involving direct application of harsh conditions, such as strong inorganic acids (e.g., H2SO4 and PPA) and high temperatures that are unsuitable for sensitive substrates [29], we decided to convert ketone 14 into its more activated tosyl oxime analog [30]. This transformation was expected to facilitate the subsequent Beckmann rearrangement, allowing it to proceed under milder conditions. Initially, ketone 14a was treated with hydroxylamine hydrochloride in pyridine at 80 °C. Upon completion of the oxime formation, TsCl was added directly to the reaction mixture, and the desired tosyl oxime 13a was isolated in 70%. However, this one-pot procedure was deemed only moderately efficient, prompting a slight modification. In the improved protocol, after the completion of the oxime formation, pyridine was removed in vacuo, and the reaction mixture was redissolved in DCM. Et3N and TsCl were subsequently added, leading to the isolation of the desired tosyl oxime in an excellent yield (Scheme 7). This protocol was then applied to the rest of the ketone derivative 14, furnishing tosyl oxime 13 in high yields without any significant issues. Notably, tosyl oximes 13 were crystallized from methanol and collected pure enough via simple filtration, eliminating any further need for chromatographic purification.
The next step in this methodology was the crucial Beckmann rearrangement. Tosyl oxime 13a was selected as the model compound and treated with trifluoroacetic acid (TFA) at 60 °C. A single product was isolated; however, it was not the desired isoxazoline/isoquinolinone hybrid. Instead, the compound was identified as nitrile 22a, the product of a Beckmann fragmentation reaction rather than the intended rearrangement. Although nitriles are known Beckmann rearrangement side products [31], in this case, the reaction exclusively yielded the nitrile without any trace of the expected amide product (Scheme 8). The formation of the aromatic isoxazole ring is likely responsible for this outcome, strongly driving the reaction toward the benzonitrile derivative. It seems that the carbocation intermediate (shown in Scheme 9), formed during the Beckmann rearrangement mechanism, has an extremely short lifetime, making it unable to be quenched, even by water. Nonetheless, the fact that the sp3 carbon group was the one migrating to the nitrogen atom is worth mentioning. At this point, a small-scale investigation was conducted to explore whether it was possible to increase the lifetime of this carbocation and achieve the isolation of the desired amides, even in low yields. The TFA-mediated transformation was attempted again at room temperature but failed to give any reaction. Subsequently, we excluded the acid from the reaction conditions and applied heat to 13a in an appropriate solvent. Once more, the isolated product was nitrile 22a, although the starting material required notably more time to be consumed. Next, we introduced water into the solvent system and applied heat, aiming to increase the likelihood of the carbocation intermediate being trapped by a water molecule. However, this approach also proved unsuccessful. As a final attempt, we employed solvents known to stabilize generated carbocations and potentially extend their lifetime [32,33], but the obtained product was nitrile 22a in every case (Scheme 8).
Despite the unsuccessful Beckmann rearrangement attempts, we decided to apply the TFA-mediated conditions to the previously prepared tosyl oxime derivatives (13). Additionally, the reaction scale was increased using nearly 1 g of starting material. As expected under these conditions, the formation of the nitrile was predominant in almost all entries (Table 2). Interestingly, however, the formation of additional products was observed. Primary benzamides 23 was isolated in most cases, albeit in low but notable yields ranging from 6% to 32%. It appeared reasonable to speculate that these benzamides were formed via hydrolysis of the corresponding nitriles as a post-Beckmann fragmentation transformation. Indeed, the hydrolysis of 22a to 23a was verified by conducting control experiments at 60 °C for 18 h (Table 3), which showed that nitrile 22a is slowly hydrolyzed in the presence of p-TsOH (entry 3). Notably, such behavior was not observed in the smaller-scale model reaction of 13a. To our surprise, we detected for the first time the formation of the desired isoxazoline/isoquinolinone hybrid compounds (Beckmann amides) in the reactions of four of the tosyl oximes tested.
The four tosyl oximes that underwent the rearrangement pathway, even in low yield, share a structural similarity that might explain this unexpected result, contrary to our previous observations. These derivatives bear an aromatic ring with an appropriate substituent at the ortho position (Scheme 9). This combination provides an intrinsic stabilization to the carbocation intermediate formed during the Beckmann rearrangement (25′), extending its lifetime just enough for a water molecule to attack it, ultimately leading to the formation of the amide product. That being said, this synthetic approach allows access to only certain isoxazoline/isoquinolinone hybrids (albeit in low yields), largely determined by the substrate’s structural features.
Lastly, a unique behavior was observed with mesityl derivative 13j. The respective nitrile product (22j) was isolated in a meager 12% yield, while a new, unknown compound was found to be the major product (65%). This was identified as oxime 29 (Scheme 10). The Beckmann rearrangement (or fragmentation) requires the migrating group to be in an antiperiplanar position relative to the leaving group [34,35]. In this case, the position of the nitrogen atom in the isolated products suggests that the Z-tosyl oxime isomer is the one that undergoes the reaction. While E to Z isomerization of tosyl oximes can take place under the reaction conditions, it seems that for derivative E-13j, an interaction between the tosyl and mesityl groups favors the formation of the latter, which undergoes elimination towards 29.

2.4. Isoxazoline/Isoquinolinone Hybrids via Oxidation of the Corresponding Isoxazolidines

Even though we successfully accessed some isoxazoline/isoquinolinone hybrids, the outcome was not ideal. From our previous work [17], isomeric isoxazolidines 10aa and 10ba were already available in our lab. As a last resort, we envisioned that an oxidative removal of the benzyl group could afford the corresponding desired isoxazoline derivatives. Both isomers were treated separately with DDQ in a solvent system of DCM/H2O 10:1 at room temperature [36], and indeed, the same target isoxazoline 11a was isolated (Scheme 11). Moreover, no reaction occurred when DCM was replaced with MeCN, benzene, or 1,4-dioxane, whereas CHCl3 gave similar results. Gently heating the reaction mixture to 40 °C (DCM or CHCl3) showed no spectacular difference as well. However, replacing the biphasial solvent system with wet DCM increased the productivity of the transformation (Table 4, entries 1 and 2). Interestingly, the starting material has not been consumed, even after prolonged reaction times and, practically, the ratio of product/starting material remained unchanged after 24 h.
The same protocol was then tested using selected isoxazolidine precursors as starting materials, confirming the generality of its efficiency (Table 4). Although the yields were modest (41–75%, with the remaining starting material fully recovered), this method enables the preparation of various isoxazoline/isoquinolinone hybrid compounds, potentially expands the substrate scope, and offers a feasible pathway for accessing these hybrid structures.

2.5. Evaluation of Antifungal Activity

The synthesized compounds tested are categorized into four groups according to their structure, i.e., isoxazole benzamide 23, 4-iodoisoxazole benzamide 30, isoxazoline isoquinolinone 11, and isoxazolidine isoquinolinone 10 (Figure 1). Those heterocyclic derivatives were evaluated for their antifungal activity against six fungal species using the microdilution method, and the results are presented in Table 5 and Table 6.
According to the obtained results, isoxazole benzamide 23, which showed activity at all, had MIC values ranging between 0.04 and 0.24 mg/mL and MFC values ranging between 0.08 and 0.32 mg/mL. These values are higher than the ones for the commercially available reference drug ketoconazole (MIC 0.0004–0.05 mg/mL and MFC 0.0008–0.10 mg/mL) with a deviation for the species A. niger, where the MIC/MFC values of the mycotic were 0.10 and 0.20 mg/mL, respectively (Table 5). The best activity was observed for compound 23j, with MIC in the range of 0.04–0.16 mg/mL and MFC in the range of 0.08–0.24 mg/mL. Moreover, different species showed varying sensitivity towards the compounds tested. Thus, P. funiculosum and A. niger exhibited sensitivity to all the tested compounds, whereas yeast C. albicans was resistant to seven out of fifteen of them. Compared to ketoconazole activity, most compounds were found to be superior against A. niger, and some were equally good against P. chrysogenum. 4-Iodoisoxazole benzamide 30 was active against the six fungal species, with MIC values ranging between 0.02 and 0.16 mg/mL and MFC values ranging between 0.04 and 0.32 mg/mL (Table 5). The activity of those derivatives was higher against A. niger and, actually, much higher than that of ketoconazole, while the results against P. chrysogenum are also interesting.
Isoxazoline isoquinolinone hybrid 11 was active against the six fungal species as well. Their MIC values ranged between 0.01 and 0.16 mg/mL and their MFC values ranged between 0.02 and 0.32 mg/mL (Table 6). More specifically, among those hybrids, compound 11l showed excellent activity against A. niger. Analogously, isoxazolidine isoquinolinone hybrid 10 acted on all tested micromycetes and yeasts, with MIC ranging from 0.005 to 0.16 mg/mL and MFC ranging from 0.01 to 0.32 mg/mL, showing better results for A. niger (Table 6). The most potent compound was 10bm, exhibiting 10–100-fold higher activity than ketoconazole. Additionally, derivative 10al showed excellent activity, while micromycete A. niger was also quite sensitive to hybrids 10aj and 10am.
Comparing the different libraries tested, it is obvious that collectively, isoxazolidine/isoquinolinone hybrids 10 exhibits higher activity. It is also worth noting that for each category, the best results were observed for compounds bearing relatively bulky substituents on the isoxazole-like scaffold (e.g., compounds 23j, 30b, 11l, 10aj, and 10al). Exceptions were heptyl derivatives 10am and 10bm. More interestingly, comparing those two isomers, 10bm (anti) was generally more active than 10am (syn).
Based on the above results, compounds 23j, 11l, and 10bm were selected for further evaluation since they showed, representatively for each category, the best inhibitory effect on the most tested fungi. The activity of those compounds was in vitro examined against the six selected fungal strains using a two-dimensional checkerboard with two-fold dilution in order to determine the interactions (synergism, additive effect, indifference, or antagonism) between them and the antifungal agent (ketoconazole) in combinations. The results of those experiments are presented in Table 7, and a summarized presentation is given in Figure 2. The combination of compound 23j with ketoconazole showed additive effects on all strains, except it had an indifferent effect on C. krusei. Regarding the experiments with compound 11l and ketoconazole, synergistic effects existed for one micromycete P. chrysogenum, with an FICI value of 0.375 mg/mL, and additive effects were observed for A. fumigatus and A. niger, whereas the effect was indifferent for P. funiculosum and antagonistic for C. krusei. Finally, the combination experiments of compound 10bm with ketoconazole showed synergistic effects for C. krusei (FICI 0.28) and additive effects for the rest of the strains. Notably, the three compounds exhibited completely different effects on C. krusei, while the compounds were generally found to act additively in most of the cases. Moreover, the synergistic effects observed in the two combination experiments do not correspond to strains for which the specific compounds showed the highest activity (Table 7).
Table 7. In vitro screening of compounds 23j, 11l, and 10bm in combination with ketoconazole against selected fungal strains using checkerboard methodology (mg/mL).
Table 7. In vitro screening of compounds 23j, 11l, and 10bm in combination with ketoconazole against selected fungal strains using checkerboard methodology (mg/mL).
CompoundStrainMIC1°
(Compound)		MIC2°
(K 1)		FIC1°/FIC2°
(Compound/K)		FICI
23jC. albicans0.080.01250.005/0.01251.06
C. krusei0.160.00040.08/0.00082.50
A. fumigatus0.080.0250.04/0.006250.75
A.niger0.040.100.04/0.102.00
P. funiculosum0.040.01250.04/0.003151.25
P. chrysogenum0.080.050.02/0.0250.75
11lC. albicans0.160.01250.16/0.01252
C. krusei0.160.00040.32/0.00084
A. fumigatus0.160.0250.01/0.0251.06
A.niger0.010.100.005/0.051
P. funiculosum0.040.01250.08/0.003152.25
P. chrysogenum0.160.050.01/0.01250.375
10bmC. albicans0.160.01250.16/0.01252
C. krusei0.160.00040.01/0.00020.28
A. fumigatus0.160.0250.08/0.006250.75
A.niger0.0050.100.0025/0.0250.75
P. funiculosum0.040.01250.04/0.006251.50
P. chrysogenum0.160.050.02/0.0250.625
1 K = ketoconazole.
Molecules 30 00589 g002
Figure 2. The fractional inhibitory concentration index (FICI) values of compounds 23j, 11l, and 10bm against selected fungal strains.
Figure 2. The fractional inhibitory concentration index (FICI) values of compounds 23j, 11l, and 10bm against selected fungal strains.
Molecules 30 00589 g002

3. Experimental Section

3.1. General Information

All reactions requiring anhydrous conditions were conducted under an inert (argon) atmosphere using an oven (160 °C) or flame-died (under vacuum) glassware. Anhydrous DMF was prepared by drying overnight over barium oxide (BaO), followed by decantation of the drying agent and distillation under reduced pressure. Anhydrous toluene was distilled over sodium/benzophenone. Anhydrous DCM was distilled over calcium hydride (CaH2). All anhydrous solvents were stored in pre-dried Schlenk Kjeldahl storage flasks, containing activated molecular sieves (4 Å), and they were allowed to stand for at least 24 h. All reactions requiring high temperatures were conducted in silicon oil baths. Flash column chromatography was performed by employing silica gel 60 [(40–63 μm, Merck, KGaA (Darmstadt, Germany)]. TLC plates (0.25 mm silica gel 60 F254) used for reaction monitoring were purchased from Merck KgaA (Darmstadt, Germany) and were visualized through exposure to ultraviolet light (UV) and/or exposure to an acidic solution of p-anisaldehyde or a solution of ninhydrin stain, followed by heating with a heat gun (400 °C). All commercially available reagents and solvents were purchased from Fluorochem Ltd. (Dublin, Ireland), Sigma-Aldrich (MilliporeSigma, St. Louis, MO, USA) & Merck KGaA (Darmstadt, Germany), Fischer Scientific GmbH (Scwerte, Germany), and TCI Chemicals (Tokyo, Japan) and used without further purification. Molecular sieves (3 Å and 4 Å) were activated by being heated with a propane torch in a round-bottom flask under a high vacuum for 1–2 min, and the procedure was repeated 2–3 times. Celite® 545 was purchased from Fluorochem Ltd. (Dublin, Ireland). 1H, 13C, 19F, and 2D NMR spectra were recorded with an Agilent-500/54 spectrometer. All NMR spectra were recorded at 25 °C. Proton chemical shifts are reported in parts per million (δ scale) and are calibrated relative to a residual non-deuterated solvent as an internal reference (CDCl3: δ 7.26, DMSO-d6: δ 2.5 ppm). Carbon chemical shifts are reported in parts per million (δ scale) and are referenced from the central peak of the carbon resonance of the solvent (CDCl3: δ 77.00, DMSO-d6: δ 40.00 ppm). Infrared (IR) data were recorded in a scan range from 400 to 4000 cm−1 on a Thermo Scientific Nicolet 6700 FT-IR spectrometer equipped with a diamond attenuated total reflection (ATR) stage. HRMS data were acquired using an Agilent 6540 HRMS-QTOF model equipped with a Dual AJS ESI-MS system or with a Q-TOF (Time of Flight Mass Spectrometry) Maxis Impact (Bruker Daltonics, Bremen, Germany) with an ESI source and U-HPLC Thermo Dionex UltiMate 3000 RSLC (ThermoFisher Scientific, Dreieich, Germany) pump and autosampler. Melting points were determined on an A.KRÜSS Optronic Melting Point Meters KSP1N model apparatus. Reactions under microwave irradiation were carried out using a Biotage Initiator+ microwave synthesizer.

3.2. General Procedure for the Synthesis of N-Substituted Isoquinolinones 16

To a pre-dried round-bottom flask containing NaH (90%, 101 mg, 3.78 mmoles, 1.1 equiv.), anhydrous DMF (3 mL) was added under an argon atmosphere. The reaction flask was then placed in an ice bath, and isoquinolin-1-one (15, 0.5 g, 3.44 mmoles, 1 equiv.) was dropwise added as a DMF solution (2 mL) over a period of 10 min. After stirring at 0 °C for 15 min., benzyl bromide (0.49 mL, 4.13 mmoles, 1.2 equiv.) or Boc2O (0.95 mL, 4.13 mmoles, 1.2 equiv.) was dropwise added, and the reaction mixture was stirred at room temperature for 16 h. The resulting mixture was diluted with EtOAc (10 mL), quenched with H2O (15 mL), and transferred into a separatory funnel. The organic layer was separated, and the aqueous layer was extracted with EtOAc (2 × 10 mL). The organic layers were combined, washed with saturated brine (30 mL), and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the crude mixture was purified through flash column chromatography (silica gel, n-hexane/EtOAc 10:1 to 5:1 v/v) to afford compounds 16.

3.3. General Procedure for the Preparation of Hydroxamoyl Chlorides 17

Hydroxamoyl chlorides 17 were prepared from the corresponding aldehydes following a previously reported synthetic approach [17,37] and were used without further purification.

3.4. Synthesis of 3-Bromo-2,3-dihydro-1H-inden-1-one 20

Bromide 20 was prepared following a slightly modified procedure previously reported [17,38].

3.5. General Procedure for the Preparation of Isoxazoline Adducts 14 and 21

To a round-bottom flask containing bromide 20 (1.05 g, 5 mmoles, 1 equiv.), DCM (80 mL, 16 mL/mmole) was added, and the orange solution was placed in an ice bath. Et3N (0.84 mL, 6 mmoles, 1.2 equiv.) was dropwise added over a period of 10 min, and the bright yellow solution was stirred for another 10 min at 0 °C. The corresponding hydroxamoyl chloride 17 (6 mmoles, 1.2 equiv.) was then added to the reaction mixture as a DCM solution (120 mL, 20 mL/mmole) via a pressure-equalizing dropping funnel over a period of 1 h, closely maintaining the temperature at between 0 and 5 °C. Upon completion of the addition, the yellowish mixture was stirred for another 1 h and was gradually allowed to reach room temperature. The reaction mixture was then transferred into a separatory funnel containing semi-saturated brine (250 mL), the organic layer was separated, and the aqueous layer was extracted with DCM (2 × 200 mL). The organic layers were combined, washed with saturated brine (600 mL), and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the crude mixture was purified through flash column chromatography (silica gel, n-hexane/EtOAc 20:1 to 1:1 v/v) to afford major adduct 14 and, in most cases, also minor adduct 21. All characterization and spectroscopic data for compounds 14 and 21 are given in the Supplementary Materials.

3.6. General Procedure for the One-Pot Synthesis of Tosyl Oxime 13

To a round-bottom flask containing adduct 14 (4 mmoles, 1 equiv.), pyridine (20 mL, 5 mL/mmole) and NH2OH·HCl (12 mmoles, 3 equiv.) were sequentially added at room temperature. Then, the colorless solution was stirred for 4 h at 80 °C. Upon consumption of the starting ketone, as indicated by TLC, pyridine was removed in vacuo, and the resulting mixture was redissolved with the addition of anhydrous DCM (20 mL, 5 mL/mmole) under an Ar atmosphere at room temperature. Anhydrous Et3N (1.67 mL, 12 mmoles, 3 equiv.) was added, and the reaction mixture was stirred for 15 min at that temperature, followed by the addition of TsCl (1.14 g, 6 mmoles, 1.5 equiv.) as a single portion. After stirring for 16 h at room temperature, the reaction mixture was diluted with DCM (20 mL), quenched through the addition of saturated aq. NH4Cl solution (50 mL), and transferred into a separatory funnel. The organic layer was separated, and the aqueous layer was extracted with DCM (2 × 40 mL). The organic layers were combined, washed with aq. HCl solution (2M, 100 mL) and saturated brine (100 mL), and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and MeOH (10 to 15 mL) was added to the crude mixture to completely dissolve it. After 2–3 min, the corresponding tosyl oxime 13 crystallized as white crystals and was collected via simple filtration. All characterization and spectroscopic data for compound 13 are given in the Supplementary Materials.

3.7. General Procedure for the Beckmann Rearrangement/Fragmentation

To a round-bottom flask containing tosyl oxime 13 (3 mmoles, 1 equiv.), TFA (15 mL, 5 mL/mmole) was added at room temperature. The resulting solution was stirred for 18 h at 60 °C and was then allowed to cool to room temperature. The reaction mixture was diluted with DCM (20 mL), transferred into an Erlenmeyer flask, and placed in an ice bath. A saturated aq. Na2CO3 solution (50 mL) was added portionwise under vigorous stirring, and after the effervescence subsided, the mixture was transferred into a separatory funnel. The organic layer was separated, and the aqueous one was extracted with DCM (2 × 30 mL). The organic layers were combined, washed with saturated aq. Na2CO3 solution (50 mL) and saturated brine (50 mL), and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the crude mixture was purified through flash column chromatography (silica gel, n-hexane/EtOAc 15:1 to 1:2 v/v) to give nitrile 22, benzamide 23, and in some cases, isoxazoline/isoquinolinone hybrid 11. Oxime 29 was also isolated from the reaction mixture of 13j. All characterization and spectroscopic data for compounds 11, 22, 23, and 29 are given in the Supplementary Materials.

3.8. Synthesis of Compounds 23, 30, and 10

The preparation of compounds 23, 30, and 10 was previously reported by us [17].

3.9. General Procedure for the Hydrolysis of Nitrile 22a

To a round-bottom flask containing the nitrile 22a (1 mmoles, 1 equiv.), the reagents shown in Table 3 were added at room temperature (5 mL/mmole of 96% H2SO4 or TFA were used). The resulting solution was stirred for 18 h at 60 °C and was then allowed to cool to room temperature. The reaction mixture was diluted with DCM (10 mL), transferred into an Erlenmeyer flask, and placed in an ice bath. A saturated aq. Na2CO3 solution (20 mL) was added portionwise under vigorous stirring, and after effervescence subsided, the mixture was transferred into a separatory funnel. The organic layer was separated, and the aqueous one was extracted with DCM (2 × 10 mL). The organic layers were combined, washed with saturated aq. Na2CO3 solution (20 mL) and saturated brine (20 mL), and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the crude mixture was purified through flash column chromatography (silica gel, n-hexane/EtOAc 15:1 to 1:2 v/v) to give benzamide 23a (Table 3, entries 1 and 3), whereas the starting material was fully recovered for entry 2.

3.10. General Procedure for the DDQ-Mediated Synthesis of Isoxazoline Isoquinolinone Hybrid 11

Wet DCM was prepared by adding equal volumes (1:1 v/v) of DCM and H2O into a separatory funnel. The funnel was sealed and shaken vigorously for at least 5 min, after which the two layers were left to separate. The organic layer was then collected and used as such. To a round bottom flask containing isoxazolidine isoquinolinone 10a or 10b (0.05 mmoles, 1 equiv.), wet DCM (100 mL/mmole) was added at room temperature. Subsequently, DDQ (57 mg, 0.25 mmoles, 5 equiv.) was added in a single portion, and the red-brownish mixture was stirred for 24 h at the same temperature. The reaction mixture was then diluted with DCM (5 mL), quenched through the addition of H2O (10 mL), and transferred into a separatory funnel. The organic layer was separated, and the aqueous one was extracted with DCM (2 × 10 mL). The organic layers were combined, washed with saturated aq. Na2CO3 solution (30 mL) and saturated brine (30 mL), and dried over anhydrous Na2SO4. The solvent was removed in vacuo, and the crude mixture was purified through flash column chromatography (silica gel, n-hexane/EtOAc 6:1 to 1:1 v/v) to give isoxazoline isoquinolinone hybrid 11. All characterization and spectroscopic data for compound 11 are given in the Supplementary Materials.

3.11. In Vitro Antifungal Assay

The antifungal activity of compounds was determined by the modified microdilution method [39,40]. The following fungal strains were used: Aspergillus fumigatus (clinical isolate), Aspergillus niger (ATCC 6275), Penicillium funiculosum (ATCC 36839), Penicillium chrysogenum (2761 isolate from Lomonosov Moscow State University), Candida albicans (ATCC 10231), and Candida krusei (ATCC 14243). All the tested microorganisms are deposited at the Mycological Laboratory, Department of Plant Physiology, Institute for Biological Research ‘Siniša Stankovic’—National Institute of Republic of Serbia, University of Belgrade, Serbia. Prior to the antifungal assay, fungi were cultured for 14 days on solid malt agar at 25 °C, after which the spore inoculum was prepared. Spores were washed using sterile saline and 0.1% Tween 80 (v/v), and the suspension was adjusted to a concentration of approximately 1.0 × 105 CFU in a final volume of 100 µL per well by microscopic enumeration with a cell-counting hemotocytometer (Neubauer chamber; Paul Marienfeld, Frimley, UK). The inocula were stored at 4 °C until further use. The obtained results were presented as minimal inhibitory (MIC) and minimal fungicidal concentrations (MFCs) needed to effectively retard fungal growth. Commercially available antifungal agent ketoconazole (K1003, Sigma, Deisenhofen, Germany) was used as a positive control. Five percent DMSO was used as a negative control. Experiments were repeated twice.

3.12. In Vitro 2D Checkerboard Assay

The interactions (synergism, additive effect, indifference, or antagonism) between the selected compounds (compounds that showed the best inhibitory effect on the tested fungi) and the antifungal agent (ketoconazole) in combinations on the growth of a panel of micromycetes were analyzed using a two-dimensional checkerboard with two-fold dilution. The MICs obtained were used as a starting point for further tests. For this test, 96-well microtiter plates containing malt broth growth medium combined with the tested compound and antimicrobial agent at concentrations ranging from 1/8 MIC to 2 MIC [41] in a checkerboard pattern were used. An untreated inoculum served as a control. The plates were incubated at 25 °C for 72 h.
The fractional inhibitory concentration index (FICI) was determined according to the following formula: FICI = (FIC1°/MIC1°) + (FIC2°/MIC2°).
FIC1° and FIC2° are the MIC values of the tested compounds and antibiotics in combination, while MIC1° and MIC2° are the MIC values of the individual activity of the selected agents. The results were interpreted as follows: FICI 0.5 = synergistic effect, FICI > 0.5 = additive effect, FICI > 2 = indifferent effect, and FICI > 4 = antagonistic effect. Experiments were repeated twice [42].

4. Conclusions

Herein, we presented our investigation of the synthesis of novel isoxazoline isoquinolinone hybrids. According to our original plan, those fused heterocyclic compounds could be prepared via a 1,3-dipolar cycloaddition of indenone with nitrile oxides and a subsequent Beckmann rearrangement of the tosyl oximes of the corresponding adducts. The cycloaddition with nitrile oxides occurred uneventfully and was found to be regioselective. The major adducts were transformed into the required tosyl oximes, and the Beckmann rearrangement wasthen attempted. However, the applied conditions failed to give the desired isoquinolinones, favoring instead the formation of the fragmentation products (isoxazole benzonitriles) and the related hydrolysis products (isoxazole benzamides). A mechanistic description of this outcome is also given. An alternative successful approach was adopted involving the preparation of fused isoxazoline isoquinolinone hybrids via DDQ-mediated oxidation of the corresponding isoxazolidine isoquinolinones. The synthesis of isoxazoline derivatives completes the diverse libraries of isoxazole-like benzamides and isoquinolinones that we had previously described. Representative compounds of those libraries (i.e., isoxazole and 4-iodoisoxazole benzamides, as well as isoxazoline and isoxazolidine isoquinolinones) were evaluated for their antifungal potential. In some cases, depending on the strain used and the compounds employed, very interesting activity was observed. Further examination of this activity using the 2D checkerboard methodology revealed that some compounds exhibit significant additive and synergistic effects when combined with ketoconazole. The overall synthetic schemes represent versatile methodologies for the expansion of those libraries in the future, which could clarify their antifungal behavior and determine new biological targets.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/1420-3049/30/3/589/s1. It contains data for compounds 11, 13, 14, 16, 21–23, and 29 and copies of 1H, 13C, 19F, and 2D NMR spectra of all new compounds.

Author Contributions

Conceptualization, A.E.K.; methodology, K.A.O., J.G. and A.Ć.; formal analysis, K.A.O., J.G. and A.Ć.; data curation, K.A.O., J.G. and A.Ć.; writing—original draft preparation, K.A.O., J.G., A.Ć. and A.E.K.; writing—review and editing, A.E.K.; project administration, A.E.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Ministry of Education, Science and Technological Development of the Republic of Serbia (grant number 451-03-66/2024-03/200007).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data supporting the findings of this study are available within the paper and within its Supplementary Materials published online.

Acknowledgments

This research work was supported by the Hellenic Foundation for Research and Innovation (HFRI) under the 3rd Call for HFRI PhD Fellowships (Fellowship Number 5748). K.A.O. is grateful for this fellowship. The authors express their thanks to Maroula G. Kokotou, Laboratory of Chemistry, Department of Food Science and Human Nutrition, Agricultural University of Athens, for performing the HRMS analyses of several compounds.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Tang, S.; He, J.; Sun, Y.; He, L.; She, X. Efficient and Regioselective Synthesis of 5-Hydroxy-2-isoxazolines: Versatile Synthons for Isoxazoles, β-Lactams, and γ-Amino Alcohols. J. Org. Chem. 2010, 75, 1961–1966. [Google Scholar] [CrossRef]
  2. Berthet, M.; Cheviet, T.; Dujarin, G.; Parrot, I.; Marinez, J. Isoxazolidine: A Privileged Scaffold for Organic and Medicinal Chemistry. Chem. Rev. 2016, 116, 15235–15283. [Google Scholar] [CrossRef] [PubMed]
  3. Duc, D.X.; Dung, V.C. Recent Progress in the Synthesis of Isoxazoles. Curr. Org. Chem. 2021, 25, 2938–2989. [Google Scholar] [CrossRef]
  4. Kleinbeck, F.; Carreira, E.M. Total Synthesis of Bafilomycin A1. Angew. Chem. Int. Ed. 2009, 48, 578–581. [Google Scholar] [CrossRef]
  5. Kudryavtseva, T.N.; Lamanov, A.Y.; Sysoev, P.I.; Klimova, L.G. Synthesis and Antibacterial Activity of New Acridone Derivatives Containing an Isoxazoline Fragment. Russ. J. Gen. Chem. 2020, 90, 45–49. [Google Scholar] [CrossRef]
  6. Pandhurnekar, C.P.; Pandhurnekar, H.C.; Mungole, A.J.; Butoliya, S.S.; Yadao, B.G. A Review of Recent Synthetic Strategies and Biological Activities of Isoxazole. J. Heterocycl. Chem. 2023, 60, 537–565. [Google Scholar] [CrossRef]
  7. Kumar, G.; Shankar, R. 2-Isoxazolines: A Synthetic and Medicinal Overview. ChemMedChem 2021, 16, 430–447. [Google Scholar] [CrossRef] [PubMed]
  8. Morimoto, Y.; Kitao, S.; Okita, T.; Shoji, T. Total Synthesis and Assignment of the Double-Bond Position and Absolute Configuration of (−)-Pyrinodemin A. Org. Lett. 2003, 5, 2611–2614. [Google Scholar] [CrossRef]
  9. Wei, H.; Qiao, C.; Liu, G.; Yang, Z.; Li, C.-C. Stereoselective Total Syntheses of (−)-Flueggine A and (+)-Virosaine B. Angew. Chem. 2013, 125, 648–652. [Google Scholar] [CrossRef]
  10. Serna, A.V.; Kürti, L.; Siitonen, J.H. Synthesis of (−)-Setigerumine I: Biosynthetic Origins of the Elusive Racemic Papaveraceae Isoxazolidine Alkaloids. Angew. Chem. Int. Ed. 2021, 60, 27236–27240. [Google Scholar] [CrossRef]
  11. Wang, X.; Hu, Q.; Tang, H.; Pan, X. Isoxazole/Isoxazoline Skeleton in the Structural Modification of Natural Products: A Review. Pharmaceuticals 2023, 16, 228. [Google Scholar] [CrossRef] [PubMed]
  12. Algethami, F.K.; Saidi, I.; Abdelhamid, H.N.; Elamin, M.R.; Abdulkhair, B.Y.; Chrouda, A.; Jannet, H.B. Trifluoromethylated Flavonoid-Based Isoxazoles as Antidiabetic and Anti-Obesity Agents: Synthesis, In Vitro a-Amylase Inhibitory Activity, Molecular Docking and Structure–Activity Relationship Analysis. Molecules 2021, 26, 5214. [Google Scholar] [CrossRef] [PubMed]
  13. Zhu, J.; Mo, J.; Lin, H.; Sun, H. The recent progress of isoxazole in medicinal chemistry. Bioorg. Med. Chem. 2018, 26, 3065–3075. [Google Scholar] [CrossRef] [PubMed]
  14. Zhang, H.-Z.; Zhao, Z.-L.; Zhou, C.-H. Recent advance in oxazole-based medicinal chemistry. Eur. J. Med. Chem. 2018, 144, 444–492. [Google Scholar] [CrossRef]
  15. Agrawal, N.; Mishra, P. The synthetic and therapeutic expedition of isoxazole and its analogs. Med. Chem. Res. 2018, 27, 1309–1344. [Google Scholar] [CrossRef]
  16. Shinde, Y.; Khairnar, B.; Bangale, S. Exploring the Diverse Biological Frontiers of Isoxazole: A Comprehensive Review of its Pharmacological Significance. ChemistrySelect 2024, 9, e202401423. [Google Scholar] [CrossRef]
  17. Ouzounthanasis, K.A.; Rizos, S.R.; Koumbis, A.E. A Convenient Synthesis of Novel Isoxazolidine and Isoxazole Isoquinolinones Fused Hybrids. Molecules 2024, 29, 91. [Google Scholar] [CrossRef] [PubMed]
  18. Rao, L.B.; Sreenivasulu, C.; Kishore, D.R.; Satyanarayana, G. Trending Strategies for the Synthesis of Quinolinones and Isoquinolinones. Tetrahedron 2022, 127, 133093. [Google Scholar] [CrossRef]
  19. Mesaros, E.F.; Cole, A.G.; Kultgen, S.G.; Mani, N.; Fan, K.Y.; Dugan, B.J.; Ardzinski, A.; Stever, K.; Micolochick Steuer, H.M.; Graves, I.; et al. Conformationally Constrained Isoquinolinones as Orally Efficacious Hepatitis B Capsid Assembly Modulators. ACS Med. Chem. Lett. 2024, 15, 1627–1634. [Google Scholar] [CrossRef] [PubMed]
  20. World Health Organization. Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation 2020; World Health Organization: Geneva, Switzerland, 2020; Available online: https://iris.who.int/handle/10665/332081 (accessed on 28 December 2024).
  21. Janbon, G.; Quintin, J.; Lanternier, F.; d’Enfert, C. Studying fungal pathogens of humans and fungal infections: Fungal diversity and diversity of approaches. Microbes Infect. 2019, 21, 237–245. [Google Scholar] [CrossRef] [PubMed]
  22. Perfect, J.R.; Cox, G.M.; Lee, J.Y.; Kauffman, C.A.; de Repentigny, L.; Chapman, S.W.; Morrison, V.A.; Pappas, P.; Hiemenz, J.W.; Stevens, D.A. The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis. Clin. Infect. Dis. 2001, 33, 1824–1833. [Google Scholar] [CrossRef]
  23. Talapko, J.; Juzbašić, M.; Matijević, T.; Pustijanac, E.; Bekić, S.; Kotris, I.; Škrlec, I. Candida albicans—The virulence factors and clinical manifestations of infection. J. Fungi 2021, 7, 79. [Google Scholar] [CrossRef] [PubMed]
  24. Knutsen, A.P.; Bush, R.K.; Demain, J.G.; Denning, D.W.; Dixit, A.; Fairs, A.; Greenberger, P.A.; Kariuki, B.; Kita, H.; Kurup, V.P.; et al. Fungi and allergic lower respiratory tract diseases. J. Allergy Clin. Immunol. 2012, 129, 280–291. [Google Scholar] [CrossRef] [PubMed]
  25. Yang, C.; Zhang, G.; Tang, S.; Pan, Y.; Shao, H.; Jiao, W. Dess–Martin Periodinane-Mediated Oxidative Coupling Reaction of Isoquinoline with Benzyl Bromide. Molecules 2023, 28, 923. [Google Scholar] [CrossRef] [PubMed]
  26. Nguyen, T.B.; Martel, A.; Dhal, R.; Dujardin, G. 1,3-Dipolar Cycloaddition of N-Substituted Dipolarophiles and Nitrones: Highly Efficient Solvent-Free Reaction. J. Org. Chem. 2008, 73, 2621–2632. [Google Scholar] [CrossRef]
  27. Maiuolo, L.; Bortolini, O.; De Nino, A.; Russo, B.; Gavioli, R.; Sforza, F. Modified N,O-Nucleosides: Design, Synthesis, and Anti-tumour Activity. Aust. J. Chem. 2014, 67, 670–674. [Google Scholar] [CrossRef]
  28. Nicolaou, K.C.; Li, R.; Lu, Z.; Pitsinos, E.N.; Alemany, L.B.; Aujay, M.; Lee, C.; Sandoval, J.; Gavrilyuk, J. Streamlined Total Synthesis of Shishijimicin A and Its Application to the Design, Synthesis, and Biological Evaluation of Analogues thereof and Practical Syntheses of PhthNSSMe and Related Sulfenylating Reagents. J. Am. Chem. Soc. 2018, 140, 12120–12136. [Google Scholar] [CrossRef] [PubMed]
  29. Kaur, K.; Srivastava, S. Beckmann Rearrangement Catalysis: A Review of Recent Advances. New J. Chem. 2020, 44, 18530–18572. [Google Scholar] [CrossRef]
  30. Ning, Y.; Fukuda, T.; Ikeda, H.; Otani, Y.; Kawahata, M.; Yamaguchi, K.; Ohwada, T. Revisiting Secondary Interactions in Neighboring Group Participation, Exemplified by Reactivity Changes of Iminylium Intermediates. Org. Biomol. Chem. 2017, 15, 1381–1392. [Google Scholar] [CrossRef] [PubMed]
  31. Touchette, S.J.; Dunkley, E.M.; Lowder, L.L.; Wu, J. Nucleophile-Intercepted Beckmann Fragmentation Reactions. Chem. Sci. 2019, 10, 7812–7815. [Google Scholar] [CrossRef]
  32. Arnett, E.M.; Bushick, R.D. Solvent Effects in Organic Chemistry. III. Solvation of Stable Carbonium and Ammonium Ions in Water. The Temperature Coefficient of the HR Acidity Scale. J. Am. Chem. Soc. 1964, 86, 1564–1571. [Google Scholar] [CrossRef]
  33. Hansen, T.; Vermeeren, P.; Bickelhaupt, F.M.; Hamlin, T.A. Stability of Alkyl Carbocations. Chem. Commun. 2022, 58, 12050–12053. [Google Scholar] [CrossRef]
  34. Stradling, S.S.; Hornick, D.; Lee, J.; Riley, J. A Study of Stereospecificity: The Beckmann Rearrangement. J. Chem. Educ. 1983, 60, 502–503. [Google Scholar] [CrossRef]
  35. Crosby, I.T.; Shin, J.K.; Capuano, B. The Application of the Schmidt Reaction and Beckmann Rearrangement to the Synthesis of Bicyclic Lactams: Some Mechanistic Considerations. Aust. J. Chem. 2010, 63, 211–226. [Google Scholar] [CrossRef]
  36. Zhao, Z.-N.; He, F.-K.; Wang, Y.-H.; Li, Y.-C.; Li, Z.-H.; Yang, X.-Y.; Schneider, U.; Huang, Y.-Y. Asymmetric Clicking of Alkynyl Dipolarophiles and Nitrones Catalyzed by a Well-Defined Chiral Iron Complex. ACS Catal. 2024, 14, 13291–13302. [Google Scholar] [CrossRef]
  37. Stotani, S.; Gatta, V.; Medda, F.; Padmanaban, M.; Karawajczyk, A.; Tammela, P.; Giordanetto, F.; Tzalis, D.; Collina, S. A Versatile Strategy for the Synthesis of 4,5-Dihydroxy-2,3-Pentanedione (DPD) and Related Compounds as Potential Modulators of Bacterial Quorum Sensing. Molecules 2018, 23, 2545. [Google Scholar] [CrossRef]
  38. Lu, X.; Schneider, U. Aza-Morita-Baylis-Hillman Reactions Catalyzed by a Cyclopropenylidene. Chem. Commun. 2016, 52, 12980–12983. [Google Scholar] [CrossRef] [PubMed]
  39. M07; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 11th ed. Clinical and Laboratory Standards Insitute—CLSI: Wayne, PA, USA, 2018.
  40. Tsukatani, T.; Suenaga, H.; Shiga, M.; Noguchi, K.; Ishiyama, M.; Ezoe, T.; Matsumoto, K. Comparison of the WST-8 colorimetric method and the CLSI broth microdilution method for susceptibility testing against drug-resistant bacteria. J. Microbiol. Methods 2012, 90, 160–166. [Google Scholar] [CrossRef] [PubMed]
  41. Sun, Y.; Gao, L.; He, C.; Wu, Q.; Li, M.; Zeng, T. Givinostat exhibits in vitro synergy with posaconazole against Aspergillus spp. Med. Mycol. 2017, 55, 798–802. [Google Scholar] [PubMed]
  42. Odds, F.C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 2003, 52, 1. [Google Scholar] [CrossRef]
Molecules 30 00589 sch001
Scheme 1. An example of using a key intermediate isoxazoline for the total synthesis of a natural product [4].
Scheme 1. An example of using a key intermediate isoxazoline for the total synthesis of a natural product [4].
Molecules 30 00589 sch001
Molecules 30 00589 sch002
Scheme 2. (A) Examples of naturally occurring isoxazolidine compounds [9,10]; (B) examples of medicinally designed isoxazole and isoxazoline derivatives [12].
Scheme 2. (A) Examples of naturally occurring isoxazolidine compounds [9,10]; (B) examples of medicinally designed isoxazole and isoxazoline derivatives [12].
Molecules 30 00589 sch002
Molecules 30 00589 sch003
Scheme 3. Strategies for the synthesis of isoquinolinone hybrids 7, 10a,b, and 11.
Scheme 3. Strategies for the synthesis of isoquinolinone hybrids 7, 10a,b, and 11.
Molecules 30 00589 sch003
Molecules 30 00589 sch004
Scheme 4. The initial retrosynthetic strategies towards isoxazoline/isoquinolinone hybrids.
Scheme 4. The initial retrosynthetic strategies towards isoxazoline/isoquinolinone hybrids.
Molecules 30 00589 sch004
Molecules 30 00589 sch005
Scheme 5. Attempted 1,3-dipolar cycloadditions to N-substituted isoquinolinones.
Scheme 5. Attempted 1,3-dipolar cycloadditions to N-substituted isoquinolinones.
Molecules 30 00589 sch005
Molecules 30 00589 sch006
Scheme 6. Testing cycloaddition with an in situ generated chloroxime.
Scheme 6. Testing cycloaddition with an in situ generated chloroxime.
Molecules 30 00589 sch006
Molecules 30 00589 sch007
Scheme 7. One-pot protocol for the preparation of tosyl oximes 13.
Scheme 7. One-pot protocol for the preparation of tosyl oximes 13.
Molecules 30 00589 sch007
Molecules 30 00589 sch008
Scheme 8. Beckmann fragmentation instead of rearrangement of tosyl oxime 13a.
Scheme 8. Beckmann fragmentation instead of rearrangement of tosyl oxime 13a.
Molecules 30 00589 sch008
Molecules 30 00589 sch009
Scheme 9. A possible mechanistic explanation for the Beckmann reaction products.
Scheme 9. A possible mechanistic explanation for the Beckmann reaction products.
Molecules 30 00589 sch009
Molecules 30 00589 sch010
Scheme 10. A reasonable explanation for the formation of compound 29.
Scheme 10. A reasonable explanation for the formation of compound 29.
Molecules 30 00589 sch010
Molecules 30 00589 sch011
Scheme 11. DDQ-mediated synthesis of isoxazoline 11a from the corresponding isoxazolidines.
Scheme 11. DDQ-mediated synthesis of isoxazoline 11a from the corresponding isoxazolidines.
Molecules 30 00589 sch011
Molecules 30 00589 g001
Figure 1. Compounds used in the antifungal assay.
Figure 1. Compounds used in the antifungal assay.
Molecules 30 00589 g001
Table 1. Synthesis of isoxazoline adducts 14 and 21 from various nitrile oxides.
Table 1. Synthesis of isoxazoline adducts 14 and 21 from various nitrile oxides.
Molecules 30 00589 i001
EntryR =14
(Major Cycloadduct)		21
(Minor Cycloadduct)		Yield 1
(Comb.)
1Molecules 30 00589 i00288% (14a)6% (21a)94%
2Molecules 30 00589 i00382% (14b)7% (21b)89%
3Molecules 30 00589 i00486% (14c)5% (21c)91%
4Molecules 30 00589 i00585% (14d)4% (21d)89%
5Molecules 30 00589 i00688% (14e)5% (21e)93%
6Molecules 30 00589 i00783% (14f)6% (21f)89%
7Molecules 30 00589 i00884% (14g)6% (21g)90%
8Molecules 30 00589 i00987% (14h)3% (21h)90%
9Molecules 30 00589 i01089% (14i)3% (21i)92%
10Molecules 30 00589 i01187% (14j)3% (21j)90%
11Molecules 30 00589 i01280% (14k)-80%
12Molecules 30 00589 i01389% (14l)4% (21l)93%
13Molecules 30 00589 i01470% (14m)-70%
14Molecules 30 00589 i01564% (14n)-64%
15Molecules 30 00589 i01692% (14o)-92%
1 Yield after purification by flash column chromatography based on the amount of 20 used.
Table 2. Expanding the Beckmann protocol to a wider panel of tosyl oximes.
Table 2. Expanding the Beckmann protocol to a wider panel of tosyl oximes.
Molecules 30 00589 i017
EntryR =222311Yield 1
(Comb.)
1Molecules 30 00589 i01880% (22a)10% (23a)-80%
2Molecules 30 00589 i01976% (22b)9% (23b)-85%
3Molecules 30 00589 i02075% (22c)13% (23c)-88%
4Molecules 30 00589 i02172% (22d)15% (23d)-87%
5Molecules 30 00589 i02281% (22e)8% (23e)-89%
6Molecules 30 00589 i02385% (22f)6% (23f)-91%
7Molecules 30 00589 i02457% (22g)12% (23g)10% (11g)79%
8Molecules 30 00589 i02559% (22h)22% (23h)11% (11h)92%
9Molecules 30 00589 i02686% (22i)--86%
10Molecules 30 00589 i02712% (22j)--77% 2
11Molecules 30 00589 i02854% (22k)29% (23k)13% (11k)96%
12Molecules 30 00589 i02953% (22l)32% (23l)6% (11l)91%
13Molecules 30 00589 i03071% (22m)12% (23m)-83%
14Molecules 30 00589 i03170% (22n)9% (23n)-79%
15Molecules 30 00589 i03282% (22o)9% (23o)-91%
1 Yield after purification by flash column chromatography; 2 the main product was 29 (yield 65%), as shown in Scheme 10.
Table 3. Control experiments for the hydrolysis of nitrile 22a.
Table 3. Control experiments for the hydrolysis of nitrile 22a.
Molecules 30 00589 i033
EntryReagentsYield 1
196% H2SO497%
2TFA, H2O (1 equiv.)0%
3TFA, p-TsOH (1 equiv.), H2O (1 equiv.)9%
1 Yield after purification by flash column chromatography.
Table 4. Synthesis of isoxazoline/isoquinolinone hybrids via oxidation.
Table 4. Synthesis of isoxazoline/isoquinolinone hybrids via oxidation.
Molecules 30 00589 i034
EntrySM 1R1 =R2 =Product 2BRSM
Yield 3
110aaHMolecules 30 00589 i03545% (11a)97%
210baMolecules 30 00589 i036H48% (11a)96%
310abHMolecules 30 00589 i03744% (11b)94%
410bbMolecules 30 00589 i038H47% (11b)92%
510acHMolecules 30 00589 i03953% (11c)91%
610bcMolecules 30 00589 i040H50% (11c)95%
710adHMolecules 30 00589 i04142% (11d)90%
810bdMolecules 30 00589 i042H41% (11d)89%
910agHMolecules 30 00589 i04348% (11g)93%
1010bgMolecules 30 00589 i044H51% (11g)97%
1110ahHMolecules 30 00589 i04548% (11h)93%
1210bhMolecules 30 00589 i046H45% (11h)95%
1310ajHMolecules 30 00589 i04775% (11j)93%
1410akHMolecules 30 00589 i04846% (11k)96%
1510bkMolecules 30 00589 i049H48% (11k)93%
1610alHMolecules 30 00589 i05049% (11l)95%
1710blMolecules 30 00589 i051H49% (11l)92%
1 SM = starting material; 2 yield after purification by flash column chromatography; 3 BRSM yield is the yield based on recovered starting material.
Table 5. Antifungal activity of isoxazole benzamides 23 and 30 (MIC/MFC in mg/mL).
Table 5. Antifungal activity of isoxazole benzamides 23 and 30 (MIC/MFC in mg/mL).
Compound 1C. albicansC. kruseiA. fumigatusA. nigerP. funiculosumP. chrysogenum
23aMIC0.080.160.240.160.080.16
MFC0.160.240.320.240.160.24
23bMIC--0.160.080.040.08
MFC--0.240.160.080.16
23cMIC-0.160.160.080.040.16
MFC-0.240.240.160.080.24
23dMIC-0.080.240.040.040.08
MFC-0.160.320.080.080.16
23eMIC-0.160.160.160.16-
MFC-0.240.240.240.32-
23fMIC-0.160.160.040.040.16
MFC-0.240.240.160.080.24
23gMIC-0.160.160.080.160.16
MFC 0.240.240.160.320.24
23hMIC0.160.160.160.160.080.16
MFC0.240.24-0.320.160.24
23iMIC0.160.160.160.160.16-
MFC0.240.240.240.320.24-
23jMIC0.080.160.080.040.040.08
MFC0.160.240.240.160.080.16
23kMIC0.24-0.160.160.040.08
MFC0.32-0.240.240.080.16
23lMIC0.080.080.240.040.160.16
MFC-0.160.320.080.240.24
23mMIC0.080.160.080.080.040.04
MFC0.160.240.160.160.080.08
23nMIC0.16-0.160.160.040.16
MFC0.24-0.240.240.160.24
23oMIC-0.240.240.080.080.16
MFC-0.320.320.160.160.24
30aMIC0.160.080.120.040.160.08
MFC0.320.160.160.080.320.16
30bMIC0.160.160.160.020.080.16
MFC0.320.320.240.040.160.32
30cMIC0.160.160.160.040.080.08
MFC0.320.320.320.080.160.16
30dMIC0.160.080.160.040.160.16
MFC0.320.240.240.080.240.32
K 2MIC0.01250.00040.0250.100.01250.05
MFC0.0250.00080.050.200.0250.10
1 Means no activity was observed; 2 K = ketoconazole.
Table 6. Antifungal activity of selected isoxazoline isoquinolinones and isoxazolidine isoquinolinones (MIC/MFC in mg/mL).
Table 6. Antifungal activity of selected isoxazoline isoquinolinones and isoxazolidine isoquinolinones (MIC/MFC in mg/mL).
Compound 1C. albicansC. kruseiA. fumigatusA. nigerP. funiculosumP. chrysogenum
11gMIC0.080.160.160.080.160.16
MFC0.160.320.240.160.320.24
11hMIC0.160.160.160.160.160.16
MFC0.320.320.320.320.320.32
11kMIC0.160.080.080.040.040.08
MFC0.320.160.160.080.080.16
11lMIC0.160.160.160.010.040.16
MFC0.320.320.320.020.080.32
10adMIC0.080.160.160.080.160.16
MFC0.160.320.320.160.320.24
10bdMIC0.160.160.160.040.160.08
MFC0.320.320.320.080.240.16
10ajMIC0.160.160.160.020.160.04
MFC0.320.320.320.040.240.08
10alMIC0.160.080.160.010.160.16
MFC0.320.240.320.020.320.32
10amMIC0.160.160.120.020.080.16
MFC0.320.320.240.040.160.32
10bmMIC0.160.160.160.0050.040.16
MFC0.320.320.320.010.080.32
K 2MIC0.01250.00040.0250.100.01250.05
MFC0.0250.00080.050.200.0250.10
1 Means no activity was observed; 2 K = ketoconazole.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ouzounthanasis, K.A.; Glamočlija, J.; Ćirić, A.; Koumbis, A.E. Studies of the Synthesis of Fused Isoxazoline/Isoquinolinones and Evaluation of the Antifungal Activity of Isoxazole-like Benzamide and Isoquinolinone Hybrids. Molecules 2025, 30, 589. https://doi.org/10.3390/molecules30030589

AMA Style

Ouzounthanasis KA, Glamočlija J, Ćirić A, Koumbis AE. Studies of the Synthesis of Fused Isoxazoline/Isoquinolinones and Evaluation of the Antifungal Activity of Isoxazole-like Benzamide and Isoquinolinone Hybrids. Molecules. 2025; 30(3):589. https://doi.org/10.3390/molecules30030589

Chicago/Turabian Style

Ouzounthanasis, Konstantinos A., Jasmina Glamočlija, Ana Ćirić, and Alexandros E. Koumbis. 2025. "Studies of the Synthesis of Fused Isoxazoline/Isoquinolinones and Evaluation of the Antifungal Activity of Isoxazole-like Benzamide and Isoquinolinone Hybrids" Molecules 30, no. 3: 589. https://doi.org/10.3390/molecules30030589

APA Style

Ouzounthanasis, K. A., Glamočlija, J., Ćirić, A., & Koumbis, A. E. (2025). Studies of the Synthesis of Fused Isoxazoline/Isoquinolinones and Evaluation of the Antifungal Activity of Isoxazole-like Benzamide and Isoquinolinone Hybrids. Molecules, 30(3), 589. https://doi.org/10.3390/molecules30030589

Article Metrics

Back to TopTop